Table 1

Baseline characteristics of subjects (n=16) completing the study

Age, years42.0±10.3
Disease duration, years9.1±6.5
BMI, kg/m228.2±5.2
Race/ethnicity, n (%)
 White2 (12.5%)
 African-American3 (18.8%)
 Asian3 (18.8%)
 Hispanic8 (50%)
Gender, n (%)
 Female16 (100%)
SELENA-SLEDAI1.4±1.9
SLICC/ACR DI0.8±1.2
Drugs, n (%)
 Glucocorticoids11 (68.7%)
 Antimalarials15 (93.7%)
 Azathioprine5 (31.2%)
 Methotrexate2 (12.5%)
 Mycophenolate mofetil6 (37.5%)
  • Values are means±SD or count and percentage of total sample, n=number of patients.

  • BMI, body mass index; SELENA-SLEDAI, Safety of Estrogen in Lupus Erythematosus, National Assessment modification of Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.